论文部分内容阅读
目的:探讨血脂康联合瑞舒伐他汀钙治疗糖尿病高脂血症的临床疗效。方法:选择糖尿病高脂血症患者23例作观察组,给予血脂康联合瑞舒伐他汀钙治疗,另选择同期仅接受瑞舒伐他汀钙治疗的20例糖尿病高脂血症患者作为对照组。对两组患者的临床资料进行回顾性分析。结果:治疗前后两组血糖无差异(P>0.05),观察组在TC、TG、HDL-C和LDL-C改善程度上均显著高于对照组(P<0.05);观察组和对照组总有效率分别为95.6%和70.0%,观察组明显优于对照组(P<0.05)。结论:血脂康联合瑞舒伐他汀钙治疗糖尿病高血脂症疗效确切、安全,能够迅速纠正患者血脂异常,值得临床推广应用。
Objective: To investigate the clinical efficacy of Xuezhikang and rosuvastatin calcium in the treatment of diabetic hyperlipidemia. Methods: Twenty-three patients with hyperlipidemia were selected as the observation group. Xuezhikang and rosuvastatin calcium were given to the observation group. Twenty patients with diabetes mellitus and hyperlipidemia who received only rosuvastatin calcium during the same period were selected as the control group. The clinical data of two groups were retrospectively analyzed. Results: There was no significant difference in blood glucose between the two groups before and after treatment (P> 0.05). The improvement rate of TC, TG, HDL-C and LDL-C in the observation group were significantly higher than those in the control group (P <0.05) The effective rates were 95.6% and 70.0% respectively. The observation group was significantly better than the control group (P <0.05). Conclusion: Xuezhikang combined with rosuvastatin calcium in the treatment of diabetic hyperlipidemia is effective and safe. It can quickly correct the dyslipidemia in patients and is worthy of clinical application.